Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 1017 - 1017

Published: March 18, 2025

Thyroid cancer is a very common endocrine system malignancy. Nevertheless, dearth of precise markers makes it challenging to apply precision medicine thyroid cancer. The limitations standard diagnosis techniques (fine-needle aspiration biopsy), such as indeterminate cases and inaccuracies in distinguishing between different types cancers, lead unnecessary surgeries thus warrant the development more discriminatory biomarkers improve accuracy existing diagnostic prognostic techniques. Moreover, individualized therapies for are necessary avoid overtreatment indolent lesions undertreatment high-risk progressive disease. As metabolic signatures associated with disease aggressiveness responsiveness therapy, metabolomics has been recently used biomarker discovery. This strategy enabled detection several metabolites from tissue samples or biofluids facilitate classification potentially assist therapies. In this review, we summarize utilization potential

Language: Английский